We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DOL:TSXDollarama Inc. Analysis

Data as of 2026-03-10 - not real-time

CA$197.44

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Dollarama’s stock is trading at C$197.44, well above its DCF‑derived fair value of roughly C$115 and sporting a trailing PE of 42 and a PB of 41, indicating a pronounced premium. Revenue is expanding at a robust 22% year‑over‑year and margins remain healthy (gross ~46%, operating ~23%), while the dividend yield sits at a modest 0.21% with an 8.7% payout ratio, suggesting ample room for sustainability. Technically, the price sits just above the 20‑day (C$195.19) and 50‑day (C$195.69) SMAs, the RSI is neutral at 53, and the MACD histogram is modestly positive, supporting a slight bullish bias, though the stock faces a clear support line at C$185.89 and resistance near C$203.50.
The company carries an exceptionally high debt‑to‑equity ratio (>400) and a beta of only 0.12, translating to low market‑risk sensitivity but heightened balance‑sheet vulnerability. Volatility over the past 30 days is around 22%, and the consumer‑defensive sector generally offers low to medium risk, while geographic exposure to Canada and parts of Latin America introduces a medium‑level geographic and currency risk. Upcoming Q4 FY2026 earnings on March 24 could act as a catalyst, and while analysts maintain a “Buy” consensus with a median target of C$218 (≈7% upside), the current valuation gap suggests caution. The prudent stance is a neutral‑to‑hold position across horizons, awaiting clearer earnings momentum and any deleveraging progress.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and price above short‑term SMAs
  • Support level near C$185.9 limiting downside
  • Overvaluation relative to DCF and high multiples

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and margin expansion
  • Elevated debt‑to‑equity ratio posing balance‑sheet risk
  • Upcoming earnings release could clarify valuation gap

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Sustainable dividend despite low yield
  • Defensive consumer sector offering stability
  • Premium valuation may compress unless growth accelerates

Key Metrics & Analysis

Financial Health

Revenue Growth22.20%
Profit Margin18.59%
P/E Ratio42.0
ROE102.25%
ROA15.65%
Debt/Equity415.13
P/B Ratio41.6
Op. Cash FlowCA$1.7B
Free Cash FlowCA$1.1B

Technical Analysis

TrendNeutral
RSI53.2
SupportCA$185.89
ResistanceCA$203.50
MA 20CA$195.19
MA 50CA$195.69
MA 200CA$190.53
MACDBullish
VolumeStable
Fear & Greed Index76.18

Valuation

Fair ValueCA$115.52
Target PriceCA$212.06
Upside/Downside7.41%
GradeOvervalued
TypeGrowth
Dividend Yield0.21%

Risk Assessment

Beta0.12
Volatility21.66%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.